Park National Corp OH Sells 1,712 Shares of Cencora, Inc. (NYSE:COR)

Park National Corp OH trimmed its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 4.4% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 37,334 shares of the company's stock after selling 1,712 shares during the quarter. Park National Corp OH's holdings in Cencora were worth $10,382,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Hickory Asset Management Inc. bought a new position in shares of Cencora in the fourth quarter valued at about $572,000. Sylvest Advisors LLC bought a new position in shares of Cencora in the fourth quarter valued at about $1,105,000. Vontobel Holding Ltd. raised its holdings in shares of Cencora by 46.9% in the fourth quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock valued at $1,403,000 after buying an additional 1,995 shares during the last quarter. Milestone Asset Management LLC raised its holdings in shares of Cencora by 430.2% in the fourth quarter. Milestone Asset Management LLC now owns 5,461 shares of the company's stock valued at $1,227,000 after buying an additional 4,431 shares during the last quarter. Finally, Portfolio Design Labs LLC raised its holdings in shares of Cencora by 76.9% in the fourth quarter. Portfolio Design Labs LLC now owns 11,032 shares of the company's stock valued at $2,479,000 after buying an additional 4,794 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on COR shares. Citigroup raised their price target on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Wall Street Zen upgraded Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Evercore ISI raised their price target on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Wells Fargo & Company raised their price target on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a report on Friday, March 14th. Finally, Morgan Stanley set a $288.00 price target on Cencora in a report on Tuesday, April 15th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat, Cencora has a consensus rating of "Moderate Buy" and an average price target of $301.18.

Cencora Trading Down 0.4%

Shares of Cencora stock traded down $1.17 during trading on Monday, hitting $290.08. 392,464 shares of the company were exchanged, compared to its average volume of 1,533,291. The firm has a market capitalization of $56.22 billion, a P/E ratio of 41.23, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a 1-year low of $218.65 and a 1-year high of $309.35. The firm's fifty day moving average price is $284.83 and its 200 day moving average price is $258.71. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The company had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. During the same period in the previous year, the company earned $3.80 EPS. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 2nd. Stockholders of record on Friday, May 16th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.76%. The ex-dividend date is Friday, May 16th. Cencora's dividend payout ratio (DPR) is presently 25.52%.

Insider Activity

In other news, EVP Elizabeth S. Campbell sold 4,127 shares of Cencora stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the transaction, the executive vice president now owns 14,665 shares in the company, valued at $3,934,326.20. The trade was a 21.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the transaction, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. This trade represents a 9.03% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 40,253 shares of company stock worth $11,102,417 in the last 90 days. Corporate insiders own 10.80% of the company's stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.